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Background-—The contribution of apolipoprotein A-I (apoA-I) to coronary heart disease (CHD) risk stratiﬁcation over and above
high-density lipoprotein cholesterol (HDL-C) is unclear. We studied the associations between plasma levels of HDL-C and apoA-I,
either alone or combined, with risk of CHD events and cardiovascular risk factors among apparently healthy men and women.
Methods and Results-—HDL-C and apoA-I levels were measured among 17 661 participants of the EPIC (European Prospective
Investigation into Cancer)-Norfolk prospective population study. Hazard ratios for CHD events and distributions of risk factors were
calculated by quartiles of HDL-C and apoA-I. Results were validated using data from the ARIC (Atherosclerosis Risk in Communities)
and WHS (Women’s Health Study) cohorts, comprising 15 494 and 27 552 individuals, respectively. In EPIC-Norfolk, both HDL-C and
apoA-I quartiles were strongly and inversely associated with CHD risk. Within HDL-C quartiles, higher apoA-I levels were not
associated with lower CHD risk; in fact, CHD risk was higher within some HDL-C quartiles. ApoA-I levels were associated with higher
levels of CHD risk factors: higher body mass index, HbA1c, non-HDL-C, triglycerides, apolipoprotein B, systolic blood pressure, and C-
reactive protein, within ﬁxed HDL-C quartiles. In contrast, HDL-C levels were consistently inversely associated with overall CHD risk
and CHD risk factors within apoA-I quartiles (P<0.001). These ﬁndings were validated in the ARIC and WHS cohorts.
Conclusions-—Our ﬁndings demonstrate that apoA-I levels do not offer predictive information over and above HDL-C. In fact, within
some HDL-C quartiles, higher apoA-I levels were associated with higher risk of CHD events, possibly because of the unexpected
higher prevalence of cardiovascular risk factors in association with higher apoA-I levels.
Clinical Trial Registration-—URL: https://www.clinicaltrials.gov. Unique identiﬁer: NCT00000479. ( J Am Heart Assoc. 2017;6:
e006636. DOI: 10.1161/JAHA.117.006636.)
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P rospective epidemiological studies have consistentlyshown that plasma levels of high-density lipoprotein
cholesterol (HDL-C) are inversely associated with coronary
heart disease (CHD) risk. However, the biological foundation
of this association is controversial. Mendelian randomization
studies have shown us that single nucleotide polymorphisms
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in loci only affecting plasma HDL-C levels do not associate
with CHD risk.1 The inverse association between HDL-C and
CHD risk has drawn attention to HDL-C as a pharmacolog-
ical target to reduce CHD risk. In spite of this, there is
currently no evidence in human studies that increasing HDL-
C leads to CHD event reduction.2–4 Combined, these
ﬁndings give rise to the notion that HDL-C itself might not
play a causative role in the protection against atherogenesis
and have resulted in a search for parameters that reﬂect the
physical structure or function of HDL as a more relevant
predictor of CHD risk. Apolipoprotein A-I (apoA-I), the major
constituent of HDL particles, might be such a parameter.
Similar associations with CHD risk have been reported for
apoA-I as for HDL-C,5 and antioxidant, anti-inﬂammatory,
antithrombotic, and nitric oxide–promoting properties have
been ascribed to apoA-I.6,7 These ﬁndings have driven the
development of therapeutic strategies that infuse apoA-I or
upregulate apoA-I in the liver that are currently under
investigation8 with varying clinical success.9–11 Whether
apoA-I is a more relevant therapeutic target over HDL-C is
heavily debated, however.
Prospective studies comparing the associations of apoA-I
and HDL-C with risk of future CHD events have shown
conﬂicting results.12,13 A possible explanation lies in the
intricate relationship between HDL-C and apoA-I levels that is
hard to dissect using conventional regression models. Here,
we use a new approach by assessing CHD risk based on HDL-
C and apoA-I quartiles in a 494 fashion. The objective of this
study was to assess the association of apoA-I levels with CHD
risk and CHD risk factors within ﬁxed HDL-C quartiles, and
vice versa, which requires a large study sample. We pursued
this objective in the large European Prospective Investigation
into Cancer (EPIC) Norfolk cohort, a prospective population
study based in the United Kingdom. Results were validated in
the ARIC (Atherosclerosis Risk in Communities) cohort and
the WHS (Women’s Health Study).
Methods
Study Design and Biochemical Analyses
The EPIC-Norfolk study
The EPIC-Norfolk study is a prospective population study of
25 639 male and female residents of Norfolk, United
Kingdom, aged between 39 and 79 years. The recruitment
process, study design, and population characteristics have
been published previously.14 The study was approved by the
Norfolk Local Research Ethics Committee and complies with
the declaration of Helsinki. All participants gave written
informed consent.
All individuals have been ﬂagged for mortality at the UK
Ofﬁce of National Statistics, with vital status ascertained for
the entire cohort. Death certiﬁcates were coded by trained
nosologists according to the International Classiﬁcation of
Diseases 10th revision. In addition, hospitalized participants
were identiﬁed by using their unique National Health Service
number through data linkage with the East Norfolk Health
Authority (ENCORE) database, which identiﬁes all hospital
contacts throughout England and Wales for residents of
Norfolk. Participants were identiﬁed as having developed CHD
during follow-up if they had a hospital admission and/or died
with CHD as the underlying cause during follow-up. CHD was
deﬁned as International Classiﬁcation of Diseases 10th
revision codes I20 to I25 (which includes myocardial infarc-
tion, angina, and other ischemic heart disease). We report
results with follow-up to March 31, 2008, after a mean of
12.72.3 years. Previous validation studies in this cohort
indicate a high speciﬁcity of case ascertainment.15
Blood samples were drawn at the baseline visit in either
fasting or nonfasting state. Samples were processed for assay
at the Department of Clinical Biochemistry, University of
Cambridge, or stored at 80°C. In the entire population
study, serum lipids were analyzed for total cholesterol, HDL-C,
and triglyceride on a RA-1000 analyzer (Bayer Diagnostics,
Basingstoke, UK). HDL cholesterol levels were measured after
precipitation of non-HDL particles with N,N-bis (4-sulfhobutyl)-
m-Toluidine-disodium (DSBmT) and peroxidase. Low-density
lipoprotein cholesterol levels were calculated with the
Friedewald formula.16 Serum apoA-I and apolipoprotein B
(apoB) levels were measured using rate immunonephelometry
(Behring Nephelometer BNII, Marburg, Germany) with calibra-
tion traceable to the International Federation of Clinical
Chemistry primary standards.17 Researchers and laboratory
personnel had no access to identiﬁable information and could
identify samples by number only.
The ARIC Study
The ARIC Study is a population-based prospective cohort
study of cardiovascular disease sponsored by the National
Clinical Perspective
What Is New?
• In 3 large prospective cohort studies, we found that
apolipoprotein A-I was unexpectedly associated with
increased coronary artery disease risk factors within ﬁxed
high-density lipoprotein cholesterol quartiles, and for some
quartiles this resulted in increased coronary artery disease
risk.
What Are the Clinical Implications?
• Our results indicate that apolipoprotein does not offer
predictive information over and above high-density lipopro-
tein cholesterol levels.
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Heart, Lung, and Blood Institute. ARIC originally included
15 792 individuals aged 45 to 64 years at baseline (1987–
1989), chosen by probability sampling from 4 US communi-
ties.18 Cohort members completed 4 clinic examinations each
spread over about 3 years, conducted 3 years apart
between 1987 and 1998. The data used in this study are
from the ﬁrst visit in 1987–1989. A detailed study protocol is
available on the ARIC study website (https://www2.cscc.
unc.edu/aric/).
ARIC investigators conduct continuous, comprehensive
surveillance for all cardiovascular disease–related hospitaliza-
tions and deaths in the 4 communities. CHDwas adjudicated on
the basis of published criteria.19 CHD was deﬁned as a deﬁnite
or probable myocardial infarction, deﬁnite coronary death, or
coronary revascularization procedure. Those with prevalent
CHD were excluded for incident CHD analysis. Follow-up time
ended when the participant had a CHD event, died, was lost to
follow-up, or survived until December 30, 2009 with a mean
follow-up time of 203.6 years. Serum lipids and apoA-I levels
were measured as previously reported.20
The Women’s Health Study
The WHS (NCT00000479) is a completed randomized, double-
blinded, placebo-controlled trial of low-dose aspirin and
vitamin E in the primary prevention of cardiovascular disease
and cancer in women.21,22 Randomized treatment ended in
March 2004, and participants were invited to participate in
ongoing observational follow-up. Participants were apparently
healthy female healthcare professionals, ages 45 years or
older, who were free of self-reported cardiovascular disease
and cancer at study entry (1992–1996). At the time of
enrollment, women gave written informed consent and
completed questionnaires on demographics, anthropometrics,
medical history, and lifestyle factors. They were also asked to
provide a baseline blood sample; 28 345 women did so, and
of these, a total of 27 827 had baseline lipid measurements.
We excluded women with missing values for any of the lipid or
apolipoprotein measurements (N=275), resulting in 27 552
women for this analysis. The study was approved by the
institutional review board of the Brigham and Women’s
Hospital (Boston, MA).
The end point of incident CHD was deﬁned as nonfatal
myocardial infarction, percutaneous coronary intervention,
coronary artery bypass grafting, or coronary death. Informa-
tion on the occurrence of these end points was ascertained
via annual follow-up questionnaires, letters, and telephone
calls. Following written informed consent, medical records
were obtained and reviewed by a blinded Endpoints Commit-
tee for the adjudication of all reported end points based on
predeﬁned criteria as previously described.21,22 We report
results with follow-up through 2012, after a mean of
15.83.5 years.
HDL-C was measured with a direct homogeneous poly-
ethylene-glycol assay, and apoA-I with an immunoturbidomet-
ric assay (DiaSorin, Stillwater, MN). Coefﬁcients of variation
for HDL-C and apoA-I were <3%.
Statistical Analysis
We evaluated the distribution of cardiovascular risk factors
across quartiles of HDL-C and apoA-I. Metabolic syndrome
was deﬁned as previously described.23 CRP (C-reactive
protein) and triglycerides plasma levels showed a skewed
distribution and were log-transformed before analysis. P
values for trend across quartiles (and tertiles for WHS) of
HDL-C and apoA-I were assessed in an unadjusted model
using the Jonckheere-Terpstra test. Cox proportional hazards
models were used to calculate hazard ratios and correspond-
ing 95% CI for CHD risk by quartiles of HDL-C and apoA-I,
using the lowest quartile as a reference, and event-free
survival per quartile was depicted in Kaplan–Meier curves.
Unadjusted regression models were used (model 1), as well
as regression models adjusting for sex, age, smoking, body
mass index, systolic blood pressure, diabetes mellitus, apoB,
log-transformed CRP (model 2), and log-transformed triglyc-
erides (model 3). In addition, we calculated unadjusted
hazard ratios and corresponding 95% CIs for combined
quartiles of HDL-C and apoA-I. Linear regression analysis was
used to assess correlations between HDL-C and apoA-I per
HDL-C or apoA-I quartile. Analyses were undertaken using
SPSS (version 18.0).
Results
EPIC-Norfolk
A complete data set was available for a total number of
17 661 individuals in the EPIC-Norfolk cohort. This subset did
not differ in any of the relevant baseline characteristics from
the subset for whom data were missing. A total of 2226
(12.6%) participants experienced a CHD event during follow-
up. Baseline characteristics by quartiles of HDL-C and apoA-I
are shown in Tables 1 and 2, respectively.
Risk of coronary heart disease across quartiles of HDL-
C and apoA-I
Hazard ratios for risk of CHD by HDL-C and apoA-I quartiles
are shown in Tables 3 and 4 and Figure 1. Among individuals
in the top HDL-C quartile, the hazard ratio for CHD events was
0.34 (95% CI 0.30–0.39) compared with those in the bottom
HDL-C quartile (P for linear trend <0.001). In a fully adjusted
model, the hazard ratio for CHD was 0.69 (95% CI 0.59–0.80)
for those in the top versus bottom quartile (P for linear trend
<0.001).
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Individuals in the top quartile for apoA-I had a hazard ratio
for CHD events of 0.55 (95% CI 0.49–0.62, P for linear trend
<0.001) using an unadjusted model. In a fully adjusted model
the hazard ratio was 0.75 (95% CI 0.66–0.86, P for linear
trend <0.001).
Table 5 shows the distribution of participants, CHD event
rates, and hazard ratio and corresponding 95% CI across HDL-
C and apoA-I quartiles. The event-free survival curves per
HDL-C and apoA-I quartile are shown in Figure 2. In the
majority of study participants (n=9478, 54%), HDL-C quartiles
corresponded with apoA-I quartiles. However, for 8183
participants, the HDL-C quartile and apoA-I quartile were
discordant.
Compared with study participants in the bottom quartiles
for both HDL-C and apoA-I, those in the second, third, and top
quartiles for both HDL-C and apoA-I had a hazard ratio (HR) of
0.69 (95% CI 0.59–0.81), HR 0.69 (95% CI 0.59–0.82), and HR
0.57 (95% CI 0.48–0.67), respectively. Those in the lowest
HDL-C quartile and the top apoA-I quartile were not at lower
CHD risk (HR 0.87, 95% CI 0.54–1.40). By contrast, those in
the top HDL-C quartile but the bottom apoA-I quartile were at
lower CHD risk (HR 0.47, 95% CI 0.28–0.78), and this hazard
ratio was even lower than the participants having both high
HDL-C and high apoA-I levels (HR 0.57, 95% CI 0.48–0.67).
Within each apoA-I quartile, higher HDL-C levels were
associated with lower CHD risk. By contrast, within each
HDL-C quartile, we did not ﬁnd a consistent association
between apoA-I and CHD risk. A trend towards increased CHD
risk for higher apoA-I levels in the middle HDL-C quartiles was
observed, which was signiﬁcant in the third HDL-C quartile
(P=0.005).
Distribution of risk factors across quartiles of HDL-C
and apoA-I
The distribution of risk factors across HDL-C and apoA-I
quartiles is presented in Table 6. Within ﬁxed apoA-I quartiles,
HDL-C levels were inversely associated with CHD risk factors
(all P<0.001). However, the opposite pattern was observed for
apoA-I levels within ﬁxed HDL-C quartiles. Here, apoA-I levels
were positively associated with age, female sex, body mass
index, HbA1c, non-HDL-C, triglycerides, apoB, systolic blood
pressure, and CRP (all P<0.001). Overall, groups deﬁned by
high HDL-C and low apoA-I levels consisted of relatively
healthy subjects, compared with subjects deﬁned by low HDL-
C and high apoA-I levels, where enrichment for traditional
CHD risk factors was observed.
Table 1. Baseline Characteristics by HDL Cholesterol Quartiles in the EPIC-Norfolk Study
HDL Cholesterol Quartiles
P Value1 2 3 4
N 5031 3595 4444 4591
HDL cholesterol, mmol/L 1.00.1 1.30.1 1.50.1 2.00.3 <0.001
Age, y 59.69.1 59.39.1 599.1 58.89.3 <0.001
Male sex 71% (3572) 51% (1834) 35% (1555) 19% (872) <0.001
Body mass index, kg/m2 27.33.7 26.53.67 25.93.8 24.93.5 <0.001
Diabetes mellitus, % (n) 3.0 (149) 2.1 (75) 1.8 (79) 1.2 (55) <0.001
HbA1c, % 5.41.0 5.30.8 5.30.8 5.20.7 <0.001
Systolic blood pressure, mm Hg 13618 13618 13418 13319 <0.001
Diastolic blood pressure, mm Hg 8311 8311 8211 8111 <0.001
Total cholesterol, mmol/L 6.01.2 6.21.1 6.21.1 6.31.1 <0.001
LDL cholesterol, mmol/L 4.01.0 4.11.0 4.01.0 3.71.0 <0.001
Non-HDL cholesterol, mmol/L 5.01.2 4.91.1 4.71.1 4.21.1 <0.001
Triglycerides, mmol/L 2.0 (1.5–2.7) 1.7 (1.2–2.2) 1.4 (1.0–1.9) 1.1 (0.8–1.5) <0.001
Apolipoprotein A-I, mg/dL 12922 14823 16126 18430 <0.001
Apolipoprotein B, mg/dL 10025 9924 9624 9223 <0.001
C-reactive protein, mg/L 2.0 (0.9–4.3) 1.6 (0.8–3.6) 1.6 (0.8–3.5) 1.3 (0.6–2.7) <0.001
Metabolic syndrome 83% (4176) 70% (2517) 63% (2800) 56% (2571) <0.001
Alcohol intake, g/day 3.1 (0.8–9.7) 3.4 (0.8–10.5) 4.7 (0.8–10.9) 5.2 (0.9–11.8) <0.001
Data are shown as meanSD, percentage (number), or median (interquartile range). P for Jonckheere Terpstra test across categories. EPIC indicates European Prospective Investigation
into Cancer; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
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Validation in the ARIC and WHS Study
Atherosclerosis Risk in Communities (ARIC) Study
A full data set was available for 15 494 individuals of the ARIC
study. During follow-up, 2993 (19.3%) subjects experienced a
CHD event. Baseline characteristics by quartiles of HDL-C and
apoA-I are shown in Tables S1 and S2.
Risk of CHD was strongly and inversely associated with
HDL-C and apoA-I quartiles in unadjusted and fully adjusted
regression analyses (Tables S3 and S4). In a 494 analysis
by HDL-C and apoA-I quartiles, a small majority (53%,
n=8260) was classiﬁed in corresponding HDL-C and apoA-I
quartiles, whereas 7234 subjects (47%) were not. Within
ﬁxed apoA-I quartiles, HDL-C levels were associated with a
lower rate of CHD events (Table S5). However, apoA-I levels
were not consistently associated with CHD events within
ﬁxed HDL-C quartiles, which is in line with the observations
in EPIC-Norfolk. Finally, the distribution of risk factors across
Table 2. Baseline Characteristics by Apolipoprotein A-I Quartiles in the EPIC-Norfolk Study
Apolipoprotein A-I Quartiles
P Value1 2 3 4
N 4325 4514 4403 4419
HDL cholesterol, mmol/L 1.10.3 1.30.3 1.50.3 1.80.4 <0.001
Age, y 58.69.2 59.19.1 59.39.2 59.2 <0.001
Male sex 64% (2768) 56% (2528) 36% (1585) 21% (928) <0.001
Body mass index, kg/m2 26.63.7 26.43.7 26.13.9 25.53.7 <0.001
Diabetes mellitus, % (n) 2.9 (126) 2.3 (102) 1.8 (77) 1.2 (53) <0.001
HbA1c, % 5.30.8 5.30.9 5.30.8 5.30.8 0.66
Systolic blood pressure, mm Hg 13418 13518 13519 13519 <0.001
Diastolic blood pressure, mm Hg 8211 8211 8211 8211 0.90
Total cholesterol, mmol/L 5.91.1 6.11.1 6.21.1 6.41.1 <0.001
LDL cholesterol, mmol/L 3.91.0 4.01.0 4.01.0 3.91.1 0.50
Non-HDL cholesterol, mmol/L 4.71.2 4.81.2 4.71.2 4.61.2 <0.001
Triglycerides, mmol/L 1.7 (1.2–2.4) 1.6 (1.1–2.2) 1.4 (1.0–2.0) 1.3 (0.9–1.8) <0.001
Apolipoprotein A-I, mg/dL 11518 1455 1646 19917 <0.001
Apolipoprotein B, mg/dL 8827 10023 9923 9923 <0.001
C-reactive protein, mg/L 1.9 (0.9–4.4) 1.8 (0.8–3.6) 1.5 (0.8–3.1) 1.5 (0.7–3.3) <0.001
Metabolic syndrome 71% (3071) 78% (3521) 69% (3038) 55% (2431) <0.001
Alcohol intake, g/day 3.1 (0.8–9.6) 4.7 (0.8–10.9) 4.1 (0.8–10.9) 5.1 (0.8–11.7) <0.001
Data are shown as meanSD, percentage (number), or median (interquartile range). P for Jonckheere Terpstra trend test across categories. EPIC indicates European Prospective
Investigation into Cancer; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
Table 3. Risk of CHD Events by HDL Cholesterol Quartiles in the EPIC-Norfolk Study
HDL Cholesterol Quartiles
P Value
1 2 3 4
<1.1 mmol/L 1.1 to 1.4 mmol/L 1.4 to 1.7 mmol/L ≥1.7 mmol/L
Cases/total 963/5031 479/3595 465/4444 319/4591
Model 1 1.00 0.67 (0.60–0.74) 0.52 (0.47–0.58) 0.34 (0.30–0.39) <0.001
Model 2 1.00 0.81 (0.73–0.91) 0.77 (0.69–0.87) 0.61 (0.53–0.71) <0.001
Model 3 1.00 0.85 (0.76–0.95) 0.83 (0.74–0.94) 0.69 (0.59–0.80) <0.001
Data are shown as hazard ratios and corresponding 95% CI for the risk of future coronary heart disease events. Hazard ratios were calculated by quartile, using the lowest quartile as
reference category. P value is for trend across quartiles. Model 1 indicates an unadjusted regression model. Model 2 is adjusted for sex, age, smoking, body mass index, systolic blood
pressure, apolipoprotein B, and C-reactive protein. Model 3 is adjusted for the variables in model 2 and in addition for triglycerides. CHD indicates coronary heart disease; EPIC, European
Prospective Investigation into Cancer; HDL, high-density lipoprotein.
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HDL-C and apoA-I quartiles is presented in Table S6. There
were signiﬁcant trends across the majority of the HDL-C and
apoA-I quartiles for percentage males, body mass index, non-
HDL-C, triglycerides, apoB, systolic blood pressure, and
prevalence of metabolic syndrome. The characteristics of the
individuals at the extremes of the distribution were funda-
mentally different; the group deﬁned by high HDL-C and low
apoA-I levels consisted of relatively healthy subjects com-
pared with the group deﬁned by low HDL-C and high apoA-I
levels, where an enrichment of traditional risk factors was
observed, similar to the associations observed in EPIC-
Norfolk.
The Women’s Health Study
Of the total 27 552 female participants in the WHS, 1071
(3.9%) experienced a CHD event. Because of the lower CHD
event rate, analyses were performed for tertiles of HDL-C and
apoA-I. Again, both HDL-C and apoA-I levels were strongly and
inversely associated with CHD risk in unadjusted and fully
adjusted models (Tables S7 and S8). In a 393 analysis by
apoA-I and HDL-C tertiles, 18 101 (67%) were classiﬁed in
corresponding tertiles, in contrast to 9052 (33%) participants
who were in different tertiles for HDL-C and apoA-I (Table S9).
Within ﬁxed apoA-I tertiles, higher HDL-C levels were consis-
tently associated with lower CHD risk. However, no consistent
association for apoA-I and CHD risk was observed, within
ﬁxed HDL-C tertiles. In fact, for apoA-I levels there was a trend
towards higher CHD risk, within ﬁxed HDL-C tertiles, which
was statistically signiﬁcant for the second HDL-C tertile
(P=0.002).
Discussion
We present data on the associations between plasma levels of
HDL-C and apoA-I, cardiovascular risk factors and risk of CHD
in the EPIC-Norfolk cohort. As expected, both HDL-C and
apoA-I were strongly and inversely associated with the risk of
future CHD. It is noteworthy, however, that these associations
were not interchangeable. We found that within each apoA-I
quartile, higher plasma HDL-C levels were consistently
associated with lower CHD risk. There was, however, no
Table 4. Risk of CHD Events by Apolipoprotein A-I Quartiles in the EPIC-Norfolk Study
Apolipoprotein A-I Quartiles
P Value
1 2 3 4
<135 mg/dL 135 to 154 mg/dL 154 to 177 mg/dL ≥177 mg/dL
Cases/total 701/4325 624/4514 494/4403 407/4419
Model 1 1.00 0.81 (0.73–0.90) 0.66 (0.59–0.74) 0.55 (0.49–0.62) <0.001
Model 2 1.00 0.77 (0.69–0.86) 0.74 (0.65–0.83) 0.69 (0.61–0.79) <0.001
Model 3 1.00 0.79 (0.71–0.89) 0.78 (0.69–0.88) 0.75 (0.66–0.86) <0.001
CHD indicates coronary heart disease; Data are shown as hazard ratios and corresponding 95% CI for the risk of future coronary heart disease events. Hazard ratios were calculated by
quartile, using the lowest quartile as reference category. P value is for trend across quartiles. Model 1 indicates an unadjusted regression model. Model 2 is adjusted for sex, age, smoking,
body mass index, systolic blood pressure, apolipoprotein B, and C-reactive protein. Model 3 is adjusted for the variables in model 2 and in addition for triglycerides. CHD indicates coronary
heart disease; EPIC, European Prospective Investigation into Cancer.
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Figure 1. Adjusted hazard ratios for coronary
heart disease per HDL-C (A) and apolipoprotein A-
I (B) quartile in the EPIC-Norfolk Study. Data are
shown as hazard ratios and corresponding 95% CI
for the risk of future coronary heart disease events.
Hazard ratios were calculated by quartile, using the
lowest quartile as reference category, and were
adjusted for sex, age, smoking, body mass index,
systolic blood pressure, apolipoprotein B, C-reac-
tive protein, and triglyceride levels. ApoA-I indicates
apolipoprotein A-I; EPIC, European Prospective
Investigation into Cancer; HDL-C, high-density
lipoprotein cholesterol.
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consistent reverse association between apoA-I levels and
CHD risk within each HDL-C quartile, and in the EPIC-Norfolk
study we even observed a trend towards increased risk in
some apoA-I quartiles. This was supported by the unexpected
observation that CHD risk factors were positively associated
with apoA-I levels within all HDL-C quartiles. In contrast, HDL-
C was inversely associated with CHD risk factors within apoA-
I quartiles. These ﬁndings were externally validated in both
the ARIC and WHS studies, and the fact that the observations
were consistent in these prospective studies suggests a
biologically relevant association.
A number of studies have shown that HDL-C and apoA-I
levels are inversely associated with CHD risk. In most
subjects, HDL-C and apoA-I levels are closely correlated,
and in the EPIC-Norfolk study HDL-C and apoA-I quartiles
were concordant in more than half of the participants. This
concordance might explain why HDL-C and apoA-I have
shown similar association with risk of cardiovascular events in
previous studies.5
Several studies have addressed the question of the relative
contribution and/or superiority of HDL-C and apoA-I levels to
CHD risk previously, by comparing their effects in multivari-
able adjusted regression models. In Effect of potentially
modiﬁable risk factors associated with myocardial infarction
in 52 countries (INTERHEART), the association between apoA-I
and CHD risk was stronger than for HDL-C.24 However,
INTERHEART was not a prospective study and did not assess
hazard ratios for CHD risk by quartiles of apoA-I and HDL-C.
The ERFC (Emerging Risk Factors Collaboration) reported that
when apoA-I was added to risk scores containing HDL-C, this
led to a slight improvement of cardiovascular disease
risk assessment; however, the clinical relevance was ques-
tioned.13 In fact, we reported in a previous article, based on
2349 study participants in a nested case–control set within
the EPIC-Norfolk cohort, that the negative association
between HDL-C levels and risk of major coronary events
was lost upon adjustment for apoA-I and apoB, whereas upon
adjustment for HDL-C and apoB the association between
apoA-I and risk of major coronary events was retained.25
The strong and complex relationships between HDL-C
versus apoA-I and other cardiometabolic risk factors make it
very difﬁcult to disentangle associations with risk of cardio-
vascular events, especially when using complex multivariable
adjusted regression models. Our current rigorous approach
using 494 tables to assess these independent associations
provides better insight, but can only be performed in very
large data sets from prospective cohorts, such as the EPIC-
Norfolk, ARIC, and WHS data sets.
In our study, there was no signiﬁcant association between
apoA-I quartiles with the exception of some quartiles where
CHD risk was in fact positive rather than inverse. This positive
association between CHD risk and apoA-I quartiles has not
been reported before. Our results indicate that the predictive
value of apoA-I, if anything, does not outperform the
predictive value of HDL-C.
The prevalence of CHD risk factors across quartiles of
HDL-C and apoA-I conﬁrms our observations. First, we noticed
a robust enrichment of risk factors in participants within the
lowest HDL-C but highest apoA-I quartile. In other words,
subjects with a combined phenotype of low HDL-C and high
apoA-I levels are characterized by high levels of triglycerides,
apoB, and CRP, and high prevalence of hypertension and
metabolic syndrome. Second, we observed that whereas HDL-
C quartiles are inversely correlated with all analyzed cardio-
vascular risk factors, people with the highest apoA-I levels
within each HDL-C quartile are characterized by a high
Table 5. Risk of CHD Events by HDL Cholesterol and Apolipoprotein A-I Quartiles in the EPIC-Norfolk Study
HDL Cholesterol Quartiles
P Value1 2 3 4
ApoA-I quartiles
1 572/2923 77/615 36/476 16/302 <0.001
1.00 0.86 (0.67–1.09) 0.61 (0.43–0.85) 0.47 (0.28–0.78)
2 301/1605 214/1658 97/978 12/273 <0.001
0.91 (0.79–1.05) 0.69 (0.59–0.81) 0.65 (0.52–0.81) 0.35 (0.19–0.63)
3 72/397 143/1039 199/1924 80/1043 <0.001
0.88 (0.68–1.12) 0.75 (0.63–0.91) 0.69 (0.59–0.82) 0.59 (0.46–0.75)
4 18/97 45/283 133/1066 211/2973 <0.001
0.87 (0.54–1.40) 0.93 (0.68–1.26) 0.81 (0.67–0.99) 0.57 (0.48–0.67)
P value 0.41 0.18 0.005 0.35
Data are shown as number of coronary heart disease events/total number of study participants and unadjusted hazard ratios and corresponding 95% CI. Hazard ratios were calculated
using those in the bottom quartiles for both HDL cholesterol and apolipoprotein A-I as reference category. ApoA-I indicates apolipoprotein A-I; CHD, coronary heart disease EPIC, European
Prospective Investigation into Cancer; HDL, high-density lipoprotein.
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prevalence of risk factors; age, body mass index, triglycerides,
systolic blood pressure, CRP, prevalence of metabolic
syndrome, and percentage males were consistently higher
in participants in the top apoA-I quartile compared with those
in the lowest quartile, irrespective of the HDL-C quartile. This
phenomenon, which we found to be consistent among 3 large
prospective studies and within all HDL-C quartiles, has so far
not been described in the literature. This unexpected
association between established cardiovascular risk factors
and apoA-I was possibly not acknowledged to date because it
was masked by the very close relationship between apoA-I
and HDL-C.
A possible mechanism could be related to the increased
rate of metabolic syndrome observed in the high apoA-I
quartiles, which has been shown to coincide with high plasma
levels of endogenous corticosteroids such as glucocorti-
coids26,27 and androgens,28 which in turn leads to higher
levels of apoB and apoA-I.29 This might imply that individuals
in the high HDL-C/high apoA-I quartiles are characterized by
overproduction of not only apoB but also apoA-I.
Limitations
Several aspects of this study merit attention when interpret-
ing the results. First, although HDL-C and apoA-I measure-
ments were available in a large set of study participants, these
measurements do not inform us about the apolipoprotein
content of HDL particles and the intraindividual range of
apoA-I molecules per particle.30 Second, samples in EPIC-
Norfolk were not drawn in a fasting state, although the
majority of samples in WHS were fasting. The fact that HDL-C
and apoA-I are not strongly affected by a meal does not
exclude the possibility of spurious associations. Third, CHD
events in EPIC Norfolk were based on ICD coding for
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Figure 2. Kaplan–Meier event-free survival curves per HDL cholesterol and apolipoprotein A-I quartile in the EPIC-Norfolk Study. ApoA-I
indicates apolipoprotein A-I; EPIC, European Prospective Investigation into Cancer; HDL-C, high-density lipoprotein cholesterol.
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Table 6. Baseline Characteristics by HDL-C and apoA-I Quartiles in the EPIC-Norfolk Study
ApoA-I
Quartiles
HDL Cholesterol Quartiles
P Value1 2 3 4
Apolipoprotein A-I, mg/dL 1 11617 (2909) 11321 (604) 10820 (456) 11118 (289) <0.001
2 1435 (1605) 1466 (1658) 1475 (978) 1476 (273) <0.001
3 1636 (397) 1636 (1039) 1656 (1924) 1676 (1043) <0.001
4 18914 (97) 19113 (282) 19214 (1061) 20218 (2863) <0.001
P value <0.001 <0.001 <0.001 <0.001
HDL cholesterol, mmol/L 1 0.931.13 (2932) 1.240.05 (615) 1.480.08 (476) 1.90.32 (302) <0.001
2 1.030.09 (1605) 1.250.05 (1658) 1.460.08 (978) 1.880.23 (273) <0.001
3 1.040.09 (397) 1.260.05 (1039) 1.490.08 (1924) 1.860.18 (1043) <0.001
4 1.030.10 (97) 1.260.05 (283) 1.520.08 (1066) 2.050.30 (2973) <0.001
P value <0.001 <0.001 <0.001 <0.001
Age, y 1 59.19.1 (2932) 57.59.0 (615) 57.69.2 (476) 57.49.4 (302) <0.001
2 609.0 (1605) 599.0 (1658) 58.19.1 (978) 57.29.3 (273) <0.001
3 60.79.0 (397) 60.19.1 (1039) 59.19.0 (1924) 58.39.4 (1043) <0.001
4 61.18.6 (97) 60.88.8 (283) 60.19.2 (1066) 59.39.3 (2973) <0.001
P value <0.001 <0.001 <0.001 <0.001
Male sex 1 75.5 (2214/2932) 50.6 (311/615) 33.6 (160/476) 22.8 (69/302) <0.001
2 67.5 (1083/1605) 57.0 (945/1658) 44.0 (430/978) 22.3 (61/273) <0.001
3 52.9 (210/397) 44.7 (464/1039) 34.6 (665/1924) 24.6 (257/1043) <0.001
4 46.4 (45/97) 40.6 (115/283) 27.3 (291/775) 15.6 (464/2973) <0.001
P value <0.001 <0.001 <0.001 <0.001
Body mass index, kg/m2 1 27.13.6 (2926) 26.23.7 (614) 25.43.7 (475) 24.73.5 (302) <0.001
2 27.33.7 (1600) 26.23.4 (1657) 25.53.5 (977) 25.14.0 (273) <0.001
3 284.2 (396) 27.13.9 (1039) 263.8 (1923) 24.73.3 (1042) <0.001
4 28.33.8 (97) 27.33.9 (283) 26.53.8 (1064) 24.93.5 (2967) <0.001
P value <0.001 <0.001 <0.001 0.28
HbA1c, % 1 5.40.9 (1059) 5.20.7 (318) 5.30.8 (341) 5.20.8 (228) 0.001
2 5.41.0 (615) 5.30.8 (476) 5.31.0 (238) 5.20.8 (140) <0.001
3 5.71.2 (207) 5.30.8 (479) 5.30.8 (737) 5.20.7 (304) <0.001
4 61.5 (54) 5.60.7 (166) 5.30.7 (574) 5.30.7 (1499) <0.001
P value 0.001 <0.001 0.34 0.01
Non-HDL cholesterol, mmol/L 1 4.91.1 (2932) 4.61.1 (615) 4.51.2 (476) 41.0 (302) <0.001
2 5.21.1 (1605) 4.91.1 (1658) 4.41.1 (978) 4.11.1 (273) <0.001
3 5.31.2 (397) 5.11.1 (1039) 4.71.1 (1924) 4.31.2 (1043) <0.001
4 5.61.2 (97) 5.21.1 (283) 51.1 (1066) 4.31.1 (2973) <0.001
P value <0.001 <0.001 <0.001 <0.001
Triglycerides, mmol/L 1 2.0 (1.4–2.7) (2932) 1.4 (1.0–1.9) (615) 1.3 (1.0–1.8) (476) 1.0 (0.8–1.4) (302) <0.001
2 2.1 (1.5–2.7) (1605) 1.6 (1.1–2.1) (1658) 1.2 (0.9–1.6) (978) 1.0 (0.8–1.4) (273) <0.001
3 2.3 (1.7–2.9) (397) 1.9 (1.4–2.4) (1039) 1.4 (1.0–1.8) (1924) 1.1 (0.8–1.4) (1043) <0.001
4 2.4 (1.7–3.1) (97) 2.1 (1.5–2.7) (283) 1.6 (1.2–2.2) (1066) 1.1 (0.9–1.5) (2973) <0.001
P value <0.001 <0.001 <0.001 <0.001
Continued
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hospitalizations and death certiﬁcates, and not adjudicated
speciﬁcally for the purpose of this study, although events
were adjudicated by medical record review for WHS and ARIC.
The small numbers of participants and CHD events in the
extremes of the HDL-C and apoA-I distributions warrant
caution when interpreting the hazard ratios for these groups.
Lastly, we did not have data on diabetes mellitus duration
available and only HbA1C levels were available for 50% of the
cohort and we are therefore not fully informed on diabetes
mellitus severity or prediabetic conditions. We did adjust for
diabetes mellitus status, which was available for all study
participants, but cannot rule out that the confounding effect
of glucose metabolism might be underestimated in our study.
In conclusion, we show that both HDL-C and apoA-I are
inversely correlated with CHD risk. Our ﬁndings demonstrate
that apoA-I levels do not offer predictive information over and
above HDL-C. In fact, within ﬁxed HDL-C quartiles, higher
apoA-I levels were associated with a higher prevalence of
cardiovascular risk factors. This ﬁnding is new and unex-
pected and was found consistently among the 3 cohorts that
were studied. This could be a relevant ﬁnding in light of the
current development of apoA-I increasing strategies.
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Table 6. Continued
ApoA-I
Quartiles
HDL Cholesterol Quartiles
P Value1 2 3 4
Apolipoprotein B, mg/dL 1 9625 (2871) 7923 (577) 6619 (415) 5916 (241) <0.001
2 10623 (1601) 10122 (1653) 9421 (975) 7621 (271) <0.001
3 10922 (394) 10523 (1035) 9922 (1915) 9222 (1038) <0.001
4 11623 (95) 10923 (282) 10522 (1059) 9622 (2958) <0.001
P value <0.001 <0.001 <0.001 <0.001
Systolic blood pressure, mm Hg 1 13518 (2925) 13217 (613) 13117 (476) 13118 (302) <0.001
2 13818 (1601) 13618 (1658) 13218 (975) 13018 (273) <0.001
3 13917 (397) 13818 (1037) 13518 (1920) 13119 (1042) <0.001
4 14218 (97) 14020 (283) 13819 (1061) 13419 (2968) <0.001
P value <0.001 <0.001 <0.001 <0.001
C-reactive protein, mg/L 1 1.8 (0.8–3.8) (2897) 1.1 (0.5–2.4) (595) 0.9 (0.4–1.9) (451) 0.7 (0.3–1.4) (276) <0.001
2 2.1 (1.1–4.1) (1587) 1.5 (0.8–3.2) (1635) 1.2 (0.6–2.6) (970) 1.0 (0.5–2.3) (265) <0.001
3 2.4 (1.3–4.2) (390) 1.9 (1.0–3.7) (1024) 1.5 (0.8–3.2) (1899) 1.0 (0.5–2.0) (1024) <0.001
4 3.2 (1.6–5.7) (96) 2.2 (1.2–4.9) (280) 2.0 (1.0–4.0) (1050) 1.4 (0.7–2.9) (2931) <0.001
P value <0.001 <0.001 <0.001 <0.001
Metabolic syndrome 1 84.0 (2464/2932) 58.9 (362/615) 35.9 (171/476) 26.8 (81/302) <0.001
2 82.2 (1319/1605) 77.5 (1285/1658) 77.9 (762/978) 53.1 (145/273) <0.001
3 78.6 (312/397) 68.3 (710/1039) 66.1 (1271/1924) 72.2 (753/1043) 0.54
4 85.6 (83/97) 61.5 (174/283) 56.1 (598/1066) 53.1 (1580/2973) <0.001
P value 0.02 0.97 0.30 0.07
Alcohol intake, g/d 1 6.910.7 (2830) 7.4 10.4 (539) 7.311.4 (464) 8.511.4 (297) 0.01
2 8.312.1 (1554) 8.513.0 (1616) 9.312.5 (947) 9.412.9 (268) 0.01
3 7.511.1 (385) 8.613.9 (1007) 8.813.6 (1874) 9.513.8 (1009) 0.002
4 1014.7 (90) 8.212.9 (276) 8.813.3 (1036) 9.813.6 (2876) <0.001
P value 0.003 0.36 0.59 0.10
For continuous variables, data are shown as meanSD or in case of skewed distribution, as median (interquartile range). In each cell, the number between parentheses represents the total
number of observations on which the summary estimate was based. For categorical variables, data are presented as percentage, and between parentheses number and total. P value is for
Jonckheere Terpstra trend test across categories. ApoA-I indicates apolipoprotein A-I; EPIC, European Prospective Investigation into Cancer; HDL-C, high-density lipoprotein cholesterol.
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SUPPLEMENTAL MATERIAL 
 
Table S1. Baseline characteristics by HDL cholesterol quartiles in the ARIC study 
 
  HDL cholesterol quartiles  
 1 2 3 4 p-value 
N 4148 3619 3879 3848  
HDL cholesterol, mmol/L 0.87±0.12 1.15±0.07 1.41±0.09 1.94±0.34 <0.0001 
Age, years 54.4±5.75 54.1±5.78 54.3±5.79 53.9±5.72 0.0003 
Male sex % (n) 72 (3002) 52 (1886) 36 (1378) 18 (708) <0.0001 
Body mass index, kg/m2 29.0±4.85 28.4±5.29 27.7±5.50 25.6±5.13 <0.0001 
Diabetes mellitus % (n) 15.6 (647) 10.5 (379) 8.0 (308) 4.6 (178) <0.0001 
HbA1c, % N/A N/A N/A N/A N/A 
Systolic blood pressure, mmHg 121.7±17.4 121.9±19.2 121.3±19.1 120.0±19.6 <0.0001 
Diastolic blood pressure, mmHg 73.9±10.9 74.0±11.2 73.7±11.3 73.0±11.6 <0.0001 
Total cholesterol, mmol/L 5.45±1.11 5.60±1.10 5.61±1.11 5.59±1.02 <0.0001 
LDL cholesterol, mmol/L 3.66±0.99 3.77±0.99 3.63±1.02 3.19±0.98 <0.0001 
Non-HDL cholesterol, mmol/L 4.58±1.10 4.46±1.10 4.21±1.11 3.64±1.04 <0.0001 
Triglycerides, mmol/L 1.80 (1.32-2·51) 1.34 (0.99-1.80) 1.12 (0.86-1.48) 0.89 (0.70-1.19) <0.0001 
Apolipoprotein A-I, mg/dL 105.5±18.46 122.9±17.96 137.8±19.90 167.1±28.08 <0.0001 
Apolipoprotein B, mg/dL 101.2±29.59 98.3±28.93 92.7±28.31 81.8±25.24 <0.0001 
C-reactive protein, mg/L N/A N/A N/A N/A N/A 
Metabolic syndrome % (n) 72 (2968) 44 (1588) 25 (956) 13 (490) <0.0001 
Alcohol intake, g/day 0 (0-4.31) 0 (0-5.66) 0 (0-6.47) 0 (0-8.63) <0.0001 
 
Data are shown as mean ± standard deviation, percentage (number), or median (interquartile range). P for Jonckheere Terpstra test across categories. HDL indicates high-
density lipoprotein; LDL indicates low-density lipoprotein. 
Table S2. Baseline characteristics by apolipoprotein A-I quartiles in the ARIC study 
 
  Apolipoprotein A-I quartiles  
 1 2 3 4 p-value 
N 3969 3941 3785 3799  
HDL cholesterol, mmol/L 0.96±0.22 1.18±0.24 1.40±0.28 1.83±0.44 <0.0001 
Age, years 54.2±5.76 54.2±5.79 54.1±5.83 54.2±5.68 0.5901 
Male sex % (n) 66 (2630) 53 (2094) 38 (1420) 22 (830) <0.0001 
Body mass index, kg/m2 28.6±5.04 28.1±5.24 27.6±5.44 26.4±5.41 <0.0001 
Diabetes mellitus % (n) 12.7 (502) 10.0 (393) 9.4 (357) 6.9 (260) <0.0001 
HbA1c, % N/A N/A N/A N/A N/A 
Systolic blood pressure, mmHg 120.8±17.87 121.5±18.78 121.2±19.20 121.4±19.46 0.9585 
Diastolic blood pressure, mmHg 73.2±10.86 73.9±11.26 73.9±11.50 73.5±11.42 0.4412 
Total cholesterol, mmol/L 5.38±1.08 5.51±1.06 5.63±1.11 5.72±1.07 <0.0001 
LDL cholesterol, mmol/L 3.64±0.99 3.64±0.97 3.62±1.03 3.34±1.05 <0.0001 
Non-HDL cholesterol, mmol/L 4.43±1.09 4.33±1.11 4.24±1.16 3.89±1.16 <0.0001 
Triglycerides, mmol/L 1.51 (1.10-2.15) 1.30 (0.94-1.83) 1.15 (0.85-1.64) 1.02 (0.77-1.43) <0·0001 
Apolipoprotein A-I, mg/dL 97.1±11.52 121.1±5.44 140.3±5.96 175.3±21.76 <0.0001 
Apolipoprotein B, mg/dL 97.6±28.92 95.4±28.81 93.6±29.38 87.5±28.13 <0.0001 
C-reactive protein, mg/L N/A N/A N/A N/A N/A 
Metabolic syndrome % (n) 57 (2267) 43 (1693) 33 (1241) 21 (801) <0.0001 
Alcohol intake, g/day 0 (0-4.31) 0 (0-5.86) 0 (0-6.47) 0 (0-8.63) <0.0001 
 
Data are shown as mean ± standard deviation· percentage (number), or median (interquartile range). P for Jonckheere Terpstra trend test across categories. HDL indicates 
high-density lipoprotein; LDL indicates low-density lipoprotein. 
 
Table S3. Risk of coronary heart disease events by HDL cholesterol quartiles in the ARIC study 
 
  HDL cholesterol quartiles   p-value 
 1 2 3 4  
 
0.25-1.02 
mmol/L 
1.03-1.27 
mmol/L 1.27-1.57 mmol/L  1.58-4.22 mmol/L  
cases/total 1295/4148 783/3619 607/3879 308/3848   
      
Model 1 1.00 0.62 (0.57-0.68) 0.43 (0.39-0.47) 0.21 (0.18-0.23) <0.001 
      
Model 2 1.00 0.70 (0.64-0.77) 0.57 (0.51-0.63) 0.36 (0.32-0.42) <0.001 
      
Model 3 1.00 0.75 (0.69-0.83) 0.64 (0.58-0.72) 0.44 (0.38-0.51) <0.001 
 
 
Table S4. Risk of coronary heart disease events by apolipoprotein A-I quartiles in the ARIC study 
 
 Apolipoprotein A-I quartiles  
 1 2 3 4  p-value 
 20-111 mg/dL  112-130 mg/dL  131-151 mg/dL  
152-304 
mg/dL   
cases/total 1130/3969 859/3941 598/3785 406/3799  
      
Model 1 1.00 0.71 (0.65-0.77) 0.49 (0.44-0.54)  0.32 (0.29-0.36)  <0.001 
      
Model 2 1.00 0.79 (0.72-0.86) 0.62 (0.56-0.69) 0.51 (0.46-0.58) <0.001 
      
Model 3 1.00 0.83 (0.75-0.90) 0.68 (0.61-0.75) 0.58 (0.51-0.66) <0.001 
 
Data are shown as hazard ratios and corresponding 95% confidence intervals for the risk of future coronary heart disease events. Hazard ratios were calculated by quartile, 
using the lowest quartile as reference category. Model 1 indicates an unadjusted regression model. Model 2 is adjusted for sex, age, smoking, body mass index, systolic blood 
pressure, and low-density lipoprotein cholesterol (C-reactive protein not available). Model 3 is adjusted for the variables in model 2 and in addition for triglycerides. 
 
 
 
 
 
 
Table S5. Risk of coronary heart disease events by HDL cholesterol and apolipoprotein A-I quartiles in the ARIC study 
 
 HDL cholesterol quartiles p-value 
 1 2 3 4  
ApoA-I      
quartiles      
1 842/2642  223/998 62/302 3/27 <0.001 
 1.00 0.63 (0.54-0.72)  0.56 (0.43-0.73)  0.27 (0.09-0.84)   
      
2 366/1188 304/1393 171/1147 18/213 <0.001 
 0.94 (0.83-1.06)  0.61 (0.54-0.70) 0.39 (0.33-0.46)  0.20 (0.13-0.32)   
      
3 78/275 210/1023 235/1552 75/935 <0.001 
 0.86 (0.68-1.08)  0.56 (0.48-0.65)  0.40 (0.34-0.46)  0.20 (0.16-0.25)   
      
4 9/43 46/205 139/878 212/2673 0.006 
 0.63 (0.33-1.22)  0.63 (0.47-0.85)  0.43 (0.36-0.51)  0.20 (0.17-0.23)   
      
p-value 0.043 0.257 0.411 0.082  
 
Data are shown as number of coronary heart disease events / total number of study participants· and hazard ratios and corresponding 95% confidence intervals. Hazard ratios 
were calculated using those in the bottom quartiles for both HDL cholesterol and apolipoprotein A-I as reference category. HDL indicates high-density lipoprotein; ApoA-I 
indicates apolipoprotein A-I. 
Table S6. Baseline characteristics by HDL-C and apoA-I quartiles in the ARIC study 
 
  HDL cholesterol quartiles  
    1 2 3 4 p-value  
 ApoA-I      
 quartiles      
Apolipoprotein A-I, mg/dl 1 94.9±12.15 (2642) 101.3±7.81 (998) 103.8±7.63 (302) 92.8±22.57 (27) <0.0001 
 2 119.5±5.34 (1188) 121.1±5.34 (1393) 122.3±5.32 (1147) 124.2±4.48 (213) <0.0001 
 3 137.9±5.56 (275) 138.9±5.59 (1023) 140.3±5.99 (1552) 142.5±5.70 (935) <0.0001 
 4 164.4±15.21 (43) 160.2±8.75 (205) 165.3±12.29 (878) 179.9±23.24 (2673) <0.0001 
p-value   <0.0001 <0.0001 <0.0001 <0.0001  
       
HDL cholesterol, mmol/L 1 0.84±0.13 (2642) 1.13±0.06 (998) 1.36±0.08 (302) 1.78±0.20 (27) <0.0001 
 2 0.91±0.10 (1188) 1.14±0.07 (1393) 1.39±0.08 (1147) 1.71±0.15 (213) <0.0001 
 3 0.93±0.11 (275) 1.16±0.06 (1023) 1.41±0.09 (1552) 1.76±0.15 (935) <0.0001 
 4 0.88±0.12 (43) 1.18±0.06 (205) 1.43±0.09 (878) 2.03±0.36 (2673) <0.0001 
p-value   <0.0001 <0.0001 <0.0001 <0.0001  
       
Age, years 1 54.3±5.72 (2642) 54.0±5.86 (998) 54.2±5.78 (302) 53.3±5.34 (27) 0.1139 
 2 54.5±5.76 (1188) 54.2±5.66 (1393) 54.1±5.91 (1147) 52.8±5.89 (213) 0.0011 
 3 54.6±5.90 (275) 54.2±5.80 (1023) 54.2±5.78 (1552) 53.6±5.89 (935) 0.0071 
 4 52.1±5.50 (43) 54.0±6.06 (205) 54.9±5.65 (878) 54.0±5.64 (2673) 0.0130 
p-value   0.5460 0.5426 0.0076 0.0013  
       
Male sex 1 74.4 (1966/2642) 53.6 (535/998) 40.4 (122/302) 25.9 (7/27) <0.0001 
 2 70.3 (836/1188) 54.9 (765/1393) 38.3 (439/1147) 25.4 (54/213) <0.0001 
 3 66.2 (182/275) 48.7 (498/1023) 35.6 (552/1552) 20.1 (188/935) <0.0001 
 4 41.9 (18/43) 42.9 (88/205) 30.2 (265/878) 17.2 (459/2673) <0.0001 
p-value   <0.0001 0.0015 <0.0001 0.0013  
       
Body mass index, kg/m2 1 29.0±4.76 (2641) 27.9±5.42 (996) 27.6±5.67 (302) 24.9±3.59 (27) <0.0001 
 2 28.9±4.83 (1188) 28.4±5.21 (1391) 27.4±5.59 (1147) 25.5±4.41 (212) <0.0001 
 3 29.7±5.38 (275) 28.6±5.24 (1022) 27.7±5.39 (1548) 26.0±5.31 (934) <0.0001 
 4 31.6±5.95 (43) 29.0±5.35 (204) 28.0±5.51 (878) 25.5±5.13 (2673) <0.0001 
p-value   0.1526 0.0001 0.0058 0.0451  
       
HbA1c, % 1 N/A N/A N/A N/A N/A 
 2 N/A N/A N/A N/A N/A 
 3 N/A N/A N/A N/A N/A 
 4 N/A N/A N/A N/A N/A 
p-value   N/A N/A N/A N/A  
       
Non-HDL cholesterol, mmol/L 1 4.51±1.07 (2642) 4.32±1.09 (997) 4.12±1.13 (302) 3.72±0.97 (27) <0.0001 
 2 4.66±1.10 (1188) 4.39±1.05 (1393) 4.07±1.07 (1147) 3.54±0.95 (213) <0.0001 
 3 4.79±1.19 (275) 4.62±1.14 (1022) 4.22±1.09 (1552) 3.69±1.05 (935) <0.0001 
 4 5.31±1.67 (43) 4.73±1.17(205) 4.40±1.16 (878) 3.64±1.04 (2672) <0.0001 
p-value   <0.0001 <0.0001 <0.0001 0.5208  
       
Triglycerides, mmol/L 1 1.74 (1.30-2.39) (2642) 1.20 (0.90-1.60) (998) 1.02 (0.82-1.30) (302) 0.85 (0.56-1.10) (27) <0.0001 
 2 1.81 (1.31-2.55) (1188) 1.30 (0.98-1.73) (1393) 1.04 (0.80-1.37) (1147) 0.84 (0.63-1.04) (213) <0.0001 
 3 2.22 (1.55-3.40) (275) 1.50 (1.12-1.95) (1023) 1.12 (0.87-1.47) (1552) 0.85 (0.67-1.08) (935) <0.0001 
 4 3.42 (1.90-4.91) (43) 1.72 (1.25-2.47) (205) 1.28 (0.97-1.74) (878) 0.91 (0.71-1.22) (2673) <0.0001 
p-value   <0.0001 <0.0001 <0.0001 <0.0001  
       
Apolipoprotein B, mg/dl 1 99.9±29.1 (2641) 94.3±27.5 (997) 89.6±29.8 (301) 87.3±25.7 (27) <0.0001 
 2 102.7±29.1 (1188) 96.6±28.0 (1393) 89.5±27.8 (1147) 78.9±23.9 (213) <0.0001 
 3 106.1±32.9 (275) 103.5±30.1 (1022) 92.8±27.3 (1552) 80.5±25.0 (934) <0.0001 
 4 112.2±41.9 (43) 104.3±31.2 (204) 97.7±29.6 (877) 82.4±25.4 (2673) <0.0001 
p-value   0.0001 <0.0001 <0.0001 0.0267  
       
Systolic blood pressure, mmHg 1 120.9±17.1 (2641) 120.7±19.4 (998) 119.8±19.0 (302) 114.3±18.1 (27) 0.0390 
 2 122.5±17.7 (1187) 122.2±19.4 (1391) 120.8±19.3 (1146) 115.7±16.6 (213) <0.0001 
 3 124.5±18.3 (275) 122.3±18.7 (1023) 121.0±19.5 (1551) 119.3±19.3 (934) <0.0001 
 4 128.5±16.1 (43) 122.9±19.9 (205) 123.1±18.1 (878) 120.6±19.8 (2673) <0.0001 
p-value   <0.0001 0.0479 0.0005 0.0011  
       
C-reactive protein, mg/L 1 N/A N/A N/A N/A N/A 
 2 N/A N/A N/A N/A N/A 
 3 N/A N/A N/A N/A N/A 
 4 N/A N/A N/A N/A N/A 
p-value   N/A N/A N/A N/A  
       
Metabolic syndrome 1 70.0 (1849/2642) 35.7 (356/998) 19.9 (60/302) 7.4 (2/27) <0.0001 
 2 72.3 (858/1187) 42.0 (584/1392) 20.4 (234/1147) 8.0 (17/212) <0.0001 
 3 81.1 (223/275) 51.8 (529/1022) 24.0 (373/1551) 12.4 (116/935) <0.0001 
 4 88.4 (38/43) 58.0 (119/205) 32.9 (289/878) 13.3 (355/2671) <0.0001 
p-value   0.0003 <0.0001 <0.0001 0.0738  
       
Alcohol intake, g/day 1 0 (0-4.31) (2623) 0 (0-4.31) (992) 0 (0-6.20) (301) 0 (0-5.31) (27) 0.3070 
 2 0 (0-5.66) (1183) 0 (0-5.66) (1386) 0 (0-5.93) (1143) 0 (0-7.54) (213) 0.2855 
 3 0 (0-5.86) (273) 0 (0-5.66) (1016) 0 (0-7.54) (1543) 0 (0-5.93) (930) 0.5574 
 4 0 (0-1.89) (43) 0 (0-8.04) (204) 0 (0-5.66) (872) 0 (0-9.56) (2658) <0.0001 
p-value   0.2109 0.1830 0.9514 <0.0001  
 
 
For continuous variables data are shown as mean ± standard deviation or in case of skewed distribution, as median (interquartile range). In each cell the number between 
parentheses represents the total number of observations on which the summary estimate was based. For categorical variables, data are presented as percentage, and between 
parentheses number and total.  P-value is for Jonckheere Terpstra trend test across categories. HDL indicates high-density lipoprotein; LDL indicates low-density lipoprotein; 
ApoA-I indicates apolipoprotein A-I. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S7. Risk of coronary heart disease events by HDL cholesterol tertiles in WHS 
 
  HDL cholesterol tertiles p-value 
 1 2 3   
 < 44 mg/dL 44 – 55 mg/dL > 55 mg/dL   
cases/total 514/7487 287/8780 270/11285    
      
Model 1 1·00 0.45 (0.39-0.53) 0.33 (0.28-0.38)  <0·001 
      
Model 2 1·00 0.50 (0.43-0.58) 0.40 (0.34-0.47)  <0·001 
      
Model 3 1·00 0.56 (0.48-0.66) 0.49 (0.41-0.59)  <0·001 
      
Model 4 1·00 0.58 (0.49-0.68) 0.50 (0.42-0.60)  <0·001 
 
 
Table S8. Risk of coronary heart disease events by apolipoprotein A-I tertiles in WHS 
 
 Apolipoprotein A-I tertiles  
 1 2 3  p-value 
 < 132 mg/dL  132-150 mg/dL  > 150 mg/dL     
cases/total 381/6729 283/7564 407/13259   
      
Model 1 1·00 0.64 (0.55-0.75) 0.52 (0.45-0.60)  <0·001 
      
Model 2 1·00 0.64 (0.55-0.75) 0.52 (0.44-0.60)  <0·001 
      
Model 3 1·00 0.69 (0.58-0.81) 0.57 (0.49-0.68)  <0·001 
      
Model 4 1.00 0.72 (0.61-0.84) 0.61 (0.52-0.72)  <0·001 
 
Data are shown as hazard ratios and corresponding 95% confidence intervals for the risk of future coronary heart disease events. Hazard ratios were calculated by quartile, 
using the lowest quartile as reference category. Model 1 indicates an unadjusted regression model. Model 2 is adjusted for age, randomized treatment assignment, hormone 
use, smoking, body mass index, blood pressure, low-density lipoprotein cholesterol and C-reactive protein. Model 3 is adjusted for the variables in model 2 and in addition for 
triglycerides.  Model 4 is adjusted for the variables in model 3 plus diabetes. 
 
Table S9. Risk of coronary heart disease events by HDL cholesterol and apolipoprotein A-I tertiles in WHS 
 
 HDL cholesterol tertiles p-value 
 1 2 3   
ApoA-I      
tertiles      
1 336/4940 42/1584 3/205  <0·001 
 1.00 0.37 (0.27-0.51) 0.19 (0.06-0.60)   
      
 
2 130/1980 117/4032 36/1552  <0·001 
 0.95 (0.78-1.16) 0.40 (0.33-0.50) 0.32 (0.23-0.45)   
      
 
3 48/567 128/3164 231/9129  <0·001 
 1.23 (0.91-1.6) 0.57 (0.46-0.70) 0.33 (0.28-0.39)   
      
      
      
p-value 0.47 0.004 0.47   
 
Data are shown as number of coronary heart disease events / total number of study participants· and hazard ratios and corresponding 95% confidence intervals. Hazard ratios 
were calculated using those in the bottom tertiles for both HDL cholesterol and apolipoprotein A-I as reference category. HDL indicates high-density lipoprotein; ApoA-I 
indicates apolipoprotein A-I. 
 
 
 
 
 
